Integrated Drug Discovery Service for Infectious Disease
FUJIFILM Toyama Chemical (FFTC) provides integrated drug discovery services for infectious disease. FFTC has been engaged in small molecule drug discovery in infectious diseases for decades and has a proven track record of discovering important drugs for the treatment of infectious diseases. This is owing to our competitive advantage based on our strengths in drug discovery: insight, originality, and unconventional thinking. Our drug discovery experts embody our track record and strengths can accelerate your drug discovery through our integrated drug discovery services.
FFTC’s Anti-Infectives Drug Discovery Track Record
Over the decades of anti-infective drug discovery research, FFTC has created a number of diverse classes of anti-infectives. Of these, the beta-lactam drugs piperacillin and cefoperazon were discovered by FFTC's predecessor Toyama Chemical Co.,Ltd. and are still widely prescribed globally as a fixed dose combination with beta-lactamase inhibitors, respectively. More recently, FFTC also discovered some novel MOA anti-infectives, for example, the RNA polymerase inhibitor favipiravir, an anti-pandemic influenza virus drug, the LpxC inhibitor T-1228, which was developed as an AMR drug, and fungal respiratory chain inhibitor T-2307. As described, FFTC has an advanced infectious disease drug discovery platform established through these drug discovery and development.
Key Capabilities of FFTC’s anti-Infective Drug Discovery Platform
As described, FFTC has an advanced infectious disease drug discovery platform established through those drug discovery and development. Key capabilities of FFTC’s anti-infective drug discovery platform are summarized as follows:
- Advanced microbiology research facilities
- In vitro experiments that can adequately evaluate the efficacy of anti-infectives
- Evaluation of antimicrobial activity using diverse clinical isolates including AMR challenge panels and respiratory viruses with pandemic potential
- In vivo experiments using diverse animal models of infectious disease
- In vitro/in vivo vaccine evaluation against pathogenic microorganisms
Accessing to FFTC’s Integrated Drug Discovery Platform Enables to Identify the Candidate.
Our full integration with other platforms within FFTC allows for seamless collaboration between expert microbiologists and specialists in medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), toxicology, CMC and more. This integrated approach accelerates the progression of hit molecules towards hit to lead phase to pre-clinical and Investigational New Drug (IND) enabling stages.
For research use or further manufacturing use only. Not for use in diagnostic procedures.
Product content may differ from the actual image due to minor specification changes etc.
If the revision of product standards and packaging standards has been made, there is a case where the actual product specifications and images are different.